-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11

Benzinga·08/13/2026 15:25:11
Listen to the news
JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and lowers the price target from $12 to $11.